EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials

James A Watson, Cintia Cruz, Fabiana Barreira, Colin Forsyth, Alejandro G Schijman, Rhys Peploe, Frauke Assmus, Caitlin Naylor, Jennifer Lee, Somya Mehra, Joel Tarning, Faustino Torrico und 12 weitere

The Lancet Microbe · 2025

DOI: 10.1016/j.lanmic.2025.101156 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Lancet Microbe, 2025. Verfasst von James A Watson und 23 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Data Observatory, Oxford, UK; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford, UK. Electr…. Hauptthemen laut MEDLINE: Chagas Disease, Trypanocidal Agents, Trypanosoma cruzi. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Determining parasitological cure in chronic Chagas disease is compromised by very low blood trypomastigote densities, which fluctuate close to or below the limit of quantitative PCR (qPCR) detection (approximately one parasite per 10 mL). We aimed to improve the statistical methodology used to analyse serial qPCR data to estimate treatment efficacy. METHODS: In this secondary analysis, we pooled clinical and laboratory data from two prospective randomised controlled trials (E1224 [NCT01489228] and BENDITA [NCT03378661]) in Bolivian adults (aged 18-50 years) with chronic indeterminate Chagas disease. Both trials included positive and negative control groups, consisting of placebo and standard of care benznidazole (300 mg per day for 8 weeks), respectively. In E1224, participants were enrolled between July 19, 2011, and July 26, 2012, and the experimental groups were fosravuconazole monotherapies (400 mg per week for 4 weeks or 8 weeks, or 200 mg per week for 8 weeks); in BENDITA, participants were enrolled between Nov 30, 2016, and July 27, 2017, and the experimental groups were shorter or lower-dose benznidazole regimens (300 mg per day for 2 weeks or 4 weeks, or 150 mg per day for 4 weeks), or combinations of fosravuconazole 300 mg weekly for 8 weeks with either benznidazole 150 mg per day for 4 weeks or benznidazole 300 mg per week for 8 weeks. Triplicate qPCRs were done on one to three blood samples taken at eight to 12 follow-up visits over 1 year. The primary analysis included patients randomly assigned to placebo or patients who took an active treatment for more than 80% of the allocated treatment duration. We estimated treatment efficacy under a probabilistic hierarchical Bayesian model fitted to the serial blood qPCR data. FINDINGS: 441 patients (231 from E1224; 210 from BENDITA; 320 [73%] female and 121 [27%] male) provided 34 804 individual qPCR cycle threshold values over 5402 unique visits, comprising 449 patient-years of follow-up. In the per-protocol population (n=424), an estimated 81% (70-89) of participants had parasitological cure following the standard of care 8-week benznidazole regimen. In comparison, spontaneous self-cure occurred in only 4% of patients allocated to placebo (95% credible interval [CrI] 1-9). All benznidazole regimens had similar estimated cure proportions (95% CrIs >63%) except the 2-week regimen (63% cured [43-81]; posterior probability of inferiority relative to standard of care 8 weeks was 0·95). Fosravuconazole showed dose dependency in both efficacy and risk of increased liver aminotransferases but overall was relatively ineffective (all regimens had

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chagas DiseaseTrypanocidal AgentsTrypanosoma cruziHumansAdultMaleFemaleMiddle AgedNitroimidazolesAdolescentYoung AdultTreatment OutcomeChronic DiseaseImidazolesProspective StudiesBoliviaProof of Concept StudyReal-Time Polymerase Chain ReactionThiazolesTriazoles

Substanzen

Trypanocidal AgentsbenzonidazoleNitroimidazolesImidazolesER 30346ThiazolesTriazoles

Autor:innen und Institutionen

  • Infectious Diseases Data Observatory, Oxford, UK; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford, UK. Electronic address: james.watson@ndm.ox.ac.uk.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford, UK; Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Drugs for Neglected Diseases initiative, Rio de Janeiro, Brasil.
  • Drugs for Neglected Diseases initiative, Geneva, Switzerland.
  • Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Dr Hector Torres, CONICET, Laboratorio de Biología Molecular de la Enfermedad de Chagas, Ciudad de Buenos Aires, Argentina.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford, UK; Infectious Diseases Data Observatory, Oxford, UK.

Förderung

  • Wellcome Trust

Zitieren

APA

Watson, J. A., Cruz, C., Barreira, F., Forsyth, C., Schijman, A. G., Peploe, R., Assmus, F., Naylor, C., Lee, J., Mehra, S., Tarning, J., Torrico, F., Gascon, J., Ortiz, L., Ribeiro, I., Sosa-Estani, S., Tipple, C., Hugonnet, S., Guérin, P. J., …, & BENDITA Study Groups (2025). Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials. The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2025.101156

Vancouver

Watson JA, Cruz C, Barreira F, Forsyth C, Schijman AG, Peploe R, et al. Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials. The Lancet Microbe. 2025. doi:10.1016/j.lanmic.2025.101156

BibTeX
@article{Watson2025,
  author = {Watson, James A and Cruz, Cintia and Barreira, Fabiana and Forsyth, Colin and Schijman, Alejandro G and Peploe, Rhys and Assmus, Frauke and Naylor, Caitlin and Lee, Jennifer and Mehra, Somya and Tarning, Joel and Torrico, Faustino and Gascon, Joaquim and Ortiz, Lourdes and Ribeiro, Isabela and Sosa-Estani, Sergio and Tipple, Craig and Hugonnet, Stéphane and Guérin, Philippe J and Fraisse, Laurent and Pinazo, Maria-Jesus and White, Nicholas J and E1224, E1224 and BENDITA Study Groups, BENDITA Study Groups},
  title = {Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials},
  journal = {The Lancet Microbe},
  year = {2025},
  doi = {10.1016/j.lanmic.2025.101156}
}
Kostenlos starten →